Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
CONCLUSIONS: This study of AAV patients with severe renal disease demonstrates that the outcomes appear equivalent when treated with RTX and GC with or without concomitant CYC.
PMID: 25986390 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)
